Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban
| Autor: | Jaime Masjuan, Alicia DeFelipe |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Pyridines Non valvular atrial fibrillation 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound Antithrombotic treatment 0302 clinical medicine Edoxaban Internal medicine Atrial Fibrillation Secondary Prevention medicine Humans In patient cardiovascular diseases Stroke Randomized Controlled Trials as Topic Secondary prevention business.industry General Neuroscience Warfarin Atrial fibrillation General Medicine medicine.disease Thiazoles Clinical Trials Phase III as Topic chemistry Cardiology business 030217 neurology & neurosurgery Factor Xa Inhibitors medicine.drug |
| Zdroj: | International Journal of Neuroscience. 127:716-725 |
| ISSN: | 1543-5245 0020-7454 |
| DOI: | 10.1080/00207454.2016.1232256 |
| Popis: | Patients with atrial fibrillation and prior stroke or transient ischemic attack exhibit a very high risk of recurrence. Secondary prevention with oral anticoagulants is mandatory. Overall, clinical guidelines recommend the use of target-specific oral anticoagulants over vitamin K antagonists for secondary prevention of stroke in patients with atrial fibrillation. However, many patients with atrial fibrillation and previous stroke are not receiving the appropriate antithrombotic treatment, perhaps due to the perceived risks of anticoagulation including the risk of hemorrhagic transformation of an ischemic stroke. The ENGAGE AF-TIMI 48 trial showed that although edoxaban 60 mg and warfarin reduced the risk of stroke to a similar extent, edoxaban exhibited a lesser risk of bleeding, particularly intracranial hemorrhage. Importantly, these data were independent of the presence of prior stroke or transient ischemic attack. Therefore, edoxaban can be used in both primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation. The aim of this review was to update the available evidence about edoxaban in the clinical management of secondary prevention in individuals with non-valvular atrial fibrillation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|